Photo from wikipedia
Schizophrenia (SCZ) is a heterogeneous disease with approximately 10% of patients initially diagnosed with schizophrenia having autoantibodies binding to the NMDA receptor and presenting as anti-NMDAR encephalitis.1 Therefore, immune modulating… Click to show full abstract
Schizophrenia (SCZ) is a heterogeneous disease with approximately 10% of patients initially diagnosed with schizophrenia having autoantibodies binding to the NMDA receptor and presenting as anti-NMDAR encephalitis.1 Therefore, immune modulating therapy may frequently respond well and timely for treating patients with anti-NMDAR encephalitis characterized by psychosis.2 This article is protected by copyright. All rights reserved.
Keywords:
modulating therapy;
encephalitis;
receptor;
immune modulating;
psychosis
Journal Title: Psychiatry and Clinical Neurosciences
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Psychiatry and Clinical Neurosciences
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!